Tatyana V. Vavilova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatyana V. Vavilova has a total of 481 co-authors. Here are the top co-authors by number of shared publications:
- Olga V. Sirotkina
Almazov National Medical Research Centre
15 shared publications - Yuliya I. Zhilenkova
Almazov National Medical Research Center
10 shared publications - Elena Yu. Vasilyeva
Almazov National Medical Research Centre
9 shared publications - Maria L. Pospelova
Federal State Budgetary Institution “V. A. Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
8 shared publications - Maria A. Simakova
Almazov National Medical Research Centre
7 shared publications - Mariya Petrovna Topuzova
Almazov National Medical Research Center
7 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 329-339
he role of red cell indices in the differential diagnosis of hypochromic anaemia in pregnant women
Introduction . Microcytic hypochromic anemia in pregnant women is most often caused by iron deficiency, but a similar laboratory picture is characteristic of beta-thalassemia minor (BTM), which requires a different approach to diagnosis and management of pregnancy. Aim : to identify informative parameters of the complete blood count and calculated red blood cell indices for their use as screening for BTM in pregnant women with microcytic hypochromic anemia. Materials and Methods. The analysis included the results of blood sample testing from 36 pregnant women (gestational age 9–34 weeks) with laboratory signs of microcytic hypochromic anemia: 12 with BTM and 24 with iron defi ciency anemia (IDA). The pregnant women included in the study underwent a complete blood count with reticulocyte parameters and erythrocyte subpopulations, and the Mentzer, Sirdah, M-H index, and Urrechaga erythrocyte indices were calculated. Results . In BTM, higher values of MCHC, RET, MicroR, and RPI and lower RDW-SD, RDW-CV, and NRBC were found (p < 0.05). The greatest diagnostic informativeness was established for the Urrechaga index (AUC = 0.920; cut-off >7.6; sensitivity 90.9 %, specifi city 79.2 %) and the M-H index (AUC = 0.909; cut-off > 35.1; sensitivity 90.9 %, specifi city 87.5 %). For the Mentzer index, the AUC was 0.663, sensitivity — 54.5 %, specifi city — 75.0 %. The obtained threshold values for Urrechaga and M-H differed substantially from those previously proposed for non-pregnant women. Conclusion . The Urrechaga and M-H red cell indices are the most informative for screening for BTM in pregnant women, taking into account the change in discriminant values.
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 329-339
Open Accesshe role of red cell indices in the differential diagnosis of hypochromic anaemia in pregnant women
Introduction . Microcytic hypochromic anemia in pregnant women is most often caused by iron deficiency, but a similar laboratory picture is characteristic of beta-thalassemia minor (BTM), which requires a different approach to diagnosis and management of pregnancy. Aim : to identify informative parameters of the complete blood count and calculated red blood cell indices for their use as screening for BTM in pregnant women with microcytic hypochromic anemia. Materials and Methods. The analysis included the results of blood sample testing from 36 pregnant women (gestational age 9–34 weeks) with laboratory signs of microcytic hypochromic anemia: 12 with BTM and 24 with iron defi ciency anemia (IDA). The pregnant women included in the study underwent a complete blood count with reticulocyte parameters and erythrocyte subpopulations, and the Mentzer, Sirdah, M-H index, and Urrechaga erythrocyte indices were calculated. Results . In BTM, higher values of MCHC, RET, MicroR, and RPI and lower RDW-SD, RDW-CV, and NRBC were found (p < 0.05). The greatest diagnostic informativeness was established for the Urrechaga index (AUC = 0.920; cut-off >7.6; sensitivity 90.9 %, specifi city 79.2 %) and the M-H index (AUC = 0.909; cut-off > 35.1; sensitivity 90.9 %, specifi city 87.5 %). For the Mentzer index, the AUC was 0.663, sensitivity — 54.5 %, specifi city — 75.0 %. The obtained threshold values for Urrechaga and M-H differed substantially from those previously proposed for non-pregnant women. Conclusion . The Urrechaga and M-H red cell indices are the most informative for screening for BTM in pregnant women, taking into account the change in discriminant values.
- Open Access
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Pharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Open AccessPharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- Open Access
- 11 October 2026
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 13 (4) , 388-398
Detection of blast cells on the Mindray MC-80 automatic blood cell analyzer
Background . Detection of blast cells in peripheral blood is crucial for the diagnosis, monitoring, and evaluation of treatment efficacy in hematological diseases. The introduction of digital morphology can improve the standardization of laboratory processes; however, the results of automatic preclassification require evaluation of their comparability with expert morphological assessment. Objective . To evaluate the comparability of the results of automatic blast cell preclassification and counting using the Mindray MC-80 digital morphology analyzer with the results of expert morphological verification of digital images of peripheral blood smears. Materials and Methods . The study included 205 patients with various hematological pathologies and the presence of blasts in their peripheral blood. Blast cell counts were assessed using the Mindray MC-80 and by expert verification by a morphologist. Statistical analysis included Spearman correlation, Passing-Bablok regression, and Bland-Altman analysis. Results . Blasts were detected in all smears by expert morphological verification, while automatic counting detected them in 95.1 % of cases. A highly statistically significant correlation was found between the methods: r=0.806; pConclusion . Mindray MC-80 can be used for preliminary digital pre-classification and screening detection of blasts; however, automated counting requires mandatory expert verification by a morphologist, especially when making clinical decisions near diagnostic thresholds.
- 11 October 2026
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 13 (4) , 388-398
Open AccessDetection of blast cells on the Mindray MC-80 automatic blood cell analyzer
Background . Detection of blast cells in peripheral blood is crucial for the diagnosis, monitoring, and evaluation of treatment efficacy in hematological diseases. The introduction of digital morphology can improve the standardization of laboratory processes; however, the results of automatic preclassification require evaluation of their comparability with expert morphological assessment. Objective . To evaluate the comparability of the results of automatic blast cell preclassification and counting using the Mindray MC-80 digital morphology analyzer with the results of expert morphological verification of digital images of peripheral blood smears. Materials and Methods . The study included 205 patients with various hematological pathologies and the presence of blasts in their peripheral blood. Blast cell counts were assessed using the Mindray MC-80 and by expert verification by a morphologist. Statistical analysis included Spearman correlation, Passing-Bablok regression, and Bland-Altman analysis. Results . Blasts were detected in all smears by expert morphological verification, while automatic counting detected them in 95.1 % of cases. A highly statistically significant correlation was found between the methods: r=0.806; pConclusion . Mindray MC-80 can be used for preliminary digital pre-classification and screening detection of blasts; however, automated counting requires mandatory expert verification by a morphologist, especially when making clinical decisions near diagnostic thresholds.
- 13 May 2026
- Published by Alfmed LLC in Medical alphabet
- No. 2
Secondary prevention of ishemic stroke. Use of a combination of acetylsalicylic acid with low doses of rivaraxoban in individuals with multifocal atherosclerosis
The objective of this study was to evaluate the efficacy and safety of combined antithrombotic therapy: acetylsalicylic acid 75–100 mg once daily together with rivaroxaban 2.5 mg twice daily in patients with multifocal atherosclerosis and a history of ischemic stroke of the atherothrombotic subtype. Materials and Methods. Two groups of patients with multifocal atherosclerosis (main group, control group) were selected, comprising 161 individuals who had suffered an ischemic stroke of the atherothrombotic subtype. The main group included 105 patients receiving acetylsalicylic acid 75–100 mg daily as secondary stroke prevention. The control group consisted of 65 patients receiving combined antithrombotic therapy – rivaroxaban 2.5 mg twice daily together with acetylsalicylic acid 75–100 mg. Results and Conclusion. In the group of patients with atherothrombotic ischemic stroke who received dual antiplatelet therapy, a statistically significant reduction in the number of recurrent cardiovascular events was observed, compared to the main group receiving monotherapy with acetylsalicylic acid 75–100 mg (p=0.002). These data may indicate the effectiveness of using acetylsalicylic acid 75–100 mg daily together with rivaroxaban 2.5 mg twice daily and confirm the advantages of this combination over monotherapy with acetylsalicylic acid 75–100 mg for secondary prevention of cardiovascular events. The administration of rivaroxaban 2.5 mg twice daily together with acetylsalicylic acid 75–100 mg did not lead to the development of major bleeding, including bleeding requiring hospitalization or resulting in death, which may indicate the safety of this combination.
- 13 May 2026
- Published by Alfmed LLC in Medical alphabet
- No. 2
Secondary prevention of ishemic stroke. Use of a combination of acetylsalicylic acid with low doses of rivaraxoban in individuals with multifocal atherosclerosis
The objective of this study was to evaluate the efficacy and safety of combined antithrombotic therapy: acetylsalicylic acid 75–100 mg once daily together with rivaroxaban 2.5 mg twice daily in patients with multifocal atherosclerosis and a history of ischemic stroke of the atherothrombotic subtype. Materials and Methods. Two groups of patients with multifocal atherosclerosis (main group, control group) were selected, comprising 161 individuals who had suffered an ischemic stroke of the atherothrombotic subtype. The main group included 105 patients receiving acetylsalicylic acid 75–100 mg daily as secondary stroke prevention. The control group consisted of 65 patients receiving combined antithrombotic therapy – rivaroxaban 2.5 mg twice daily together with acetylsalicylic acid 75–100 mg. Results and Conclusion. In the group of patients with atherothrombotic ischemic stroke who received dual antiplatelet therapy, a statistically significant reduction in the number of recurrent cardiovascular events was observed, compared to the main group receiving monotherapy with acetylsalicylic acid 75–100 mg (p=0.002). These data may indicate the effectiveness of using acetylsalicylic acid 75–100 mg daily together with rivaroxaban 2.5 mg twice daily and confirm the advantages of this combination over monotherapy with acetylsalicylic acid 75–100 mg for secondary prevention of cardiovascular events. The administration of rivaroxaban 2.5 mg twice daily together with acetylsalicylic acid 75–100 mg did not lead to the development of major bleeding, including bleeding requiring hospitalization or resulting in death, which may indicate the safety of this combination.
- 8 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 32 (4)
The effect of type two diabetes mellitus on platelet aggregation in patients with a history of multifocal atherosclerosis and ischemic stroke
The objective was to assess the impact of antiplatelet therapy using acetylsalicylic acid on platelet aggregation in patients with diabetes mellitus and a history of ischemic stroke. Methods and materials. Two groups of patients (target and control) were selected, comprising 72 individuals who had experienced either a lacunar or an atherothrombotic subtype of ischemic stroke within the past two years, accompanied by multifocal atherosclerosis. The target group consisted of 38 patients with type 2 diabetes mellitus, managed through hypoglycemic therapy, while the control group included 34 patients without type 2 diabetes mellitus. Results. The evaluation of aggregatometry results revealed that platelet hypoaggregation was significantly more prevalent in response to acetylsalicylic acid therapy in the group of patients without diabetes mellitus. In contrast, laboratory resistance to acetylsalicylic acid was notable predominant in the group of patients with diabetes mellitus. This resistance may indicate insufficient therapeutic efficacy in clinical practice, potentially leading to recurrent cardiovascular events. Conclusion. It is advisable to incorporate platelet aggregation capacity assessment via impedance aggegatometry as part of secondary prevention strategies for ischemic stroke to evaluate the therapeutic effectiveness of the antiplatelet drugs. Additionally, identifying excessive platelet hypoaggregation may be crucial in patients with an elevated risk of bleeding.
- 8 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 32 (4)
The effect of type two diabetes mellitus on platelet aggregation in patients with a history of multifocal atherosclerosis and ischemic stroke
The objective was to assess the impact of antiplatelet therapy using acetylsalicylic acid on platelet aggregation in patients with diabetes mellitus and a history of ischemic stroke. Methods and materials. Two groups of patients (target and control) were selected, comprising 72 individuals who had experienced either a lacunar or an atherothrombotic subtype of ischemic stroke within the past two years, accompanied by multifocal atherosclerosis. The target group consisted of 38 patients with type 2 diabetes mellitus, managed through hypoglycemic therapy, while the control group included 34 patients without type 2 diabetes mellitus. Results. The evaluation of aggregatometry results revealed that platelet hypoaggregation was significantly more prevalent in response to acetylsalicylic acid therapy in the group of patients without diabetes mellitus. In contrast, laboratory resistance to acetylsalicylic acid was notable predominant in the group of patients with diabetes mellitus. This resistance may indicate insufficient therapeutic efficacy in clinical practice, potentially leading to recurrent cardiovascular events. Conclusion. It is advisable to incorporate platelet aggregation capacity assessment via impedance aggegatometry as part of secondary prevention strategies for ischemic stroke to evaluate the therapeutic effectiveness of the antiplatelet drugs. Additionally, identifying excessive platelet hypoaggregation may be crucial in patients with an elevated risk of bleeding.
- 17 March 2026
- Published by Arterialnaya Gipertenziya in Russian Journal for Personalized Medicine
- Vol. 5 (6)
Application of the integral thrombodynamics method in clinical practice: a systematic review of publications
In laboratory diagnostics of the hemostatic system, two types of tests are used: local (point-ofcare) and integral assays. Local tests are insufficiently sensitive to hypercoagulable states, whereas integral tests allow assessment of thrombotic risk in various pathological conditions and may become an important tool for diagnosing hypercoagulation. However, significant challenges complicate the routine clinical use of integral assays. With the growing number of publications devoted to the application of the thrombodynamics method in different medical fields, there is a need to systematize the accumulated data regarding its clinical use. To perform a systematic review of publications in order to evaluate publication activity in clinical journals devoted to the use of the thrombodynamics method in clinical practice.The systematic review was conducted in accordance with PRISMA principles. Publications from 2015 to 2025 were searched in international databases (PubMed, Web of Science, Scopus) and Russian scientific electronic libraries (CyberLeninka, eLibrary). Additional manual searches were performed using reference lists of identified articles and materials available at: https://gemakor.ru/specialistam/nauchnye-publikatsii/.Retrospective, prospective observational, randomized, and non-randomized studies including ≥20 patients in which the thrombodynamics test was used to assess thrombotic risk and monitor antithrombotic therapy were included. Case reports and review articles were excluded.Analysis of the publications revealed the absence of scientific articles dedicated to evaluating and presenting the analytical characteristics of the thrombodynamics method, quality control issues, and the influence of pre-analytical factors in real clinical practice, which may lead to unreliable results.The conducted systematic review demonstrated that the thrombodynamics test represents a valuable complement to standard hemostasis assessment in a wide range of clinical situations. In all included studies, its use allowed identification of increased thrombotic readiness. Implementation of this test in clinical practice, supported by further research, may improve the effectiveness of prevention and treatment of thromboembolic complications by enabling a more personalized and evidence-based approach to prescribing antithrombotic therapy, provided that methodological requirements and quality control standards are strictly followed.
- 17 March 2026
- Published by Arterialnaya Gipertenziya in Russian Journal for Personalized Medicine
- Vol. 5 (6)
Application of the integral thrombodynamics method in clinical practice: a systematic review of publications
In laboratory diagnostics of the hemostatic system, two types of tests are used: local (point-ofcare) and integral assays. Local tests are insufficiently sensitive to hypercoagulable states, whereas integral tests allow assessment of thrombotic risk in various pathological conditions and may become an important tool for diagnosing hypercoagulation. However, significant challenges complicate the routine clinical use of integral assays. With the growing number of publications devoted to the application of the thrombodynamics method in different medical fields, there is a need to systematize the accumulated data regarding its clinical use. To perform a systematic review of publications in order to evaluate publication activity in clinical journals devoted to the use of the thrombodynamics method in clinical practice.The systematic review was conducted in accordance with PRISMA principles. Publications from 2015 to 2025 were searched in international databases (PubMed, Web of Science, Scopus) and Russian scientific electronic libraries (CyberLeninka, eLibrary). Additional manual searches were performed using reference lists of identified articles and materials available at: https://gemakor.ru/specialistam/nauchnye-publikatsii/.Retrospective, prospective observational, randomized, and non-randomized studies including ≥20 patients in which the thrombodynamics test was used to assess thrombotic risk and monitor antithrombotic therapy were included. Case reports and review articles were excluded.Analysis of the publications revealed the absence of scientific articles dedicated to evaluating and presenting the analytical characteristics of the thrombodynamics method, quality control issues, and the influence of pre-analytical factors in real clinical practice, which may lead to unreliable results.The conducted systematic review demonstrated that the thrombodynamics test represents a valuable complement to standard hemostasis assessment in a wide range of clinical situations. In all included studies, its use allowed identification of increased thrombotic readiness. Implementation of this test in clinical practice, supported by further research, may improve the effectiveness of prevention and treatment of thromboembolic complications by enabling a more personalized and evidence-based approach to prescribing antithrombotic therapy, provided that methodological requirements and quality control standards are strictly followed.
- 26 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2S)
Iron deficiency in patients with chronic thromboembolic pulmonary hypertension: prevalence, pathogenesis, and diagnostic criteria
Aim . To assess the prevalence of iron deficiency in patients with chronic thromboembolic pulmonary hypertension (CTEPH), their impact on survival and functional status, and to identify the most informative indicator for assessing iron deficiency (ID) in this group. Material and methods . The study included 283 patients with a newly diagnosed CTEPH (mean age 56,0 [44,0; 67,0] years, 47% men). All patients underwent iron metabolism (serum iron, transferrin, serum ferritin, soluble transferrin receptors), proinflammatory cytokine (interleukin (IL)-6, -8, -10 and monocyte chemotactic protein (MCP-1)), hepcidin, and endothelin-1 tests. The control group consisted of 24 healthy donors (mean age, 58 [39; 64] years; men, 46%). Results . The prevalence of anemia was 17% (n=48), and the proportion of patients with iron deficiency anemia was 78% (n=37). No differences were found in pulmonary circulation hemodynamics or functional status when comparing patients with and without anemia, nor was there an effect of anemia on three-year patient survival. An increase in the level of C-reactive protein, IL-10 and MCP-1 in patients with CTEPH and their association with iron metabolism parameters were demonstrated. Depending on the criteria used, the prevalence of ID ranged from 24,5% to 69,1%. For the transferrin saturation, a weak direct correlation was established with such prognostic indicators as the 6-minute walk test (r=0,21; p=0,032), peak oxygen consumption (r=0,26; p=0,044) and mixed venous oxygen saturation (r=0,34; p=0,040). In addition, significant differences in the severity of CTEPH were revealed when dividing into groups according to transferrin saturation value of more/less than 20%. Three-year survival analysis in patients with CTEPH revealed significant differences in survival rates for ID criteria based on soluble transferrin receptor levels (>4,4 for men; >5,0 for women (Roche Diagnostics)) and our proposed ID criteria (serum ferritin (SF) Conclusion . Evidence was obtained to support the diagnostic value of transferrin saturation for diagnosing ID in patients with CTEPH, and supplemented ID criteria were proposed for this subgroup of patients with pulmonary hypertension.
- 26 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2S)
Iron deficiency in patients with chronic thromboembolic pulmonary hypertension: prevalence, pathogenesis, and diagnostic criteria
Aim . To assess the prevalence of iron deficiency in patients with chronic thromboembolic pulmonary hypertension (CTEPH), their impact on survival and functional status, and to identify the most informative indicator for assessing iron deficiency (ID) in this group. Material and methods . The study included 283 patients with a newly diagnosed CTEPH (mean age 56,0 [44,0; 67,0] years, 47% men). All patients underwent iron metabolism (serum iron, transferrin, serum ferritin, soluble transferrin receptors), proinflammatory cytokine (interleukin (IL)-6, -8, -10 and monocyte chemotactic protein (MCP-1)), hepcidin, and endothelin-1 tests. The control group consisted of 24 healthy donors (mean age, 58 [39; 64] years; men, 46%). Results . The prevalence of anemia was 17% (n=48), and the proportion of patients with iron deficiency anemia was 78% (n=37). No differences were found in pulmonary circulation hemodynamics or functional status when comparing patients with and without anemia, nor was there an effect of anemia on three-year patient survival. An increase in the level of C-reactive protein, IL-10 and MCP-1 in patients with CTEPH and their association with iron metabolism parameters were demonstrated. Depending on the criteria used, the prevalence of ID ranged from 24,5% to 69,1%. For the transferrin saturation, a weak direct correlation was established with such prognostic indicators as the 6-minute walk test (r=0,21; p=0,032), peak oxygen consumption (r=0,26; p=0,044) and mixed venous oxygen saturation (r=0,34; p=0,040). In addition, significant differences in the severity of CTEPH were revealed when dividing into groups according to transferrin saturation value of more/less than 20%. Three-year survival analysis in patients with CTEPH revealed significant differences in survival rates for ID criteria based on soluble transferrin receptor levels (>4,4 for men; >5,0 for women (Roche Diagnostics)) and our proposed ID criteria (serum ferritin (SF) Conclusion . Evidence was obtained to support the diagnostic value of transferrin saturation for diagnosing ID in patients with CTEPH, and supplemented ID criteria were proposed for this subgroup of patients with pulmonary hypertension.
- 2 December 2025
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 25 (6)
Resolution of the council of experts on venous thromboembolic complications in obstetrics
The results of the discussion at the Expert Council of modern aspects of assessing risk factors for venous thromboembolic complications, as well as their prevention and treatment during pregnancy and the postpartum period, are presented. Proposals have been adopted for their inclusion in the clinical recommendations of the next revision.
- 2 December 2025
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 25 (6)
Resolution of the council of experts on venous thromboembolic complications in obstetrics
The results of the discussion at the Expert Council of modern aspects of assessing risk factors for venous thromboembolic complications, as well as their prevention and treatment during pregnancy and the postpartum period, are presented. Proposals have been adopted for their inclusion in the clinical recommendations of the next revision.
- Open Access
- 25 October 2025
- Published by Alfmed LLC in Medical alphabet
- No. 22,p. 65-69
The impact of physician experience on the development of machine learning in automation of general fecal examination using image processing
The creation of intelligent fecal image analysis software based on machine-learning is dependent on the quality of image annotation by experts. A pilot study revealed an extremely low degree of inter- and intra-expert agreement in recognizing morphological objects, as measured by the F1-score. Three types of discrepancies were identified: in quantity, presence, and category of objects. It is proposed to use a consensus-based approach to mitigate subjectivity and enhance the reliability of algorithms for automation of general fecal examination.
- 25 October 2025
- Published by Alfmed LLC in Medical alphabet
- No. 22,p. 65-69
Open AccessThe impact of physician experience on the development of machine learning in automation of general fecal examination using image processing
The creation of intelligent fecal image analysis software based on machine-learning is dependent on the quality of image annotation by experts. A pilot study revealed an extremely low degree of inter- and intra-expert agreement in recognizing morphological objects, as measured by the F1-score. Three types of discrepancies were identified: in quantity, presence, and category of objects. It is proposed to use a consensus-based approach to mitigate subjectivity and enhance the reliability of algorithms for automation of general fecal examination.
- Open Access
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (9) , 6529
Expert opinion on key aspects of managing education school for patients taking vitamin K antagonists
The leading problem in the use of vitamin K antagonist (VKA) therapy is the complexity and the need to maintain the international normalized ratio (INR) within therapeutic window of at least 60% of the treatment time. Obviously, the optimal solution to this problem in the context of modern technological capabilities is its self-monitoring by a patient and understanding the need to adjust the VKA (warfarin) dose to achieve the target INR values (independently or with the help of a physician’s consultation). Portable devices and a model of self-monitoring of anticoagulant therapy (coagulometers) has reduced the rates of thromboembolism, major bleeding, and all-cause mortality, and confirmed its high cost-effectiveness.An important aspect for successful INR self-monitoring is comprehensive patient education, implemented within the specialized schools. Such educational programs provide patients with the necessary knowledge about warfarin, the importance of regular INR monitoring, the aspects of self-monitoring, possible complications and actions in emergency situations. The combination of structured training and subsequent INR self-monitoring contributes to a significant increase in therapy adherence and improved clinical outcomes. The results of systematic reviews and randomized trials confirm that patient participation in educational programs reduces the risk of thromboembolic and hemorrhagic events and increases the overall effectiveness of treatment. The aim of the work was to formulate the key aspects of managing an education school for patients taking VKA.The combination of educational programs, active follow-up, coagulometers, and remote monitoring forms a holistic model for managing patients receiving VKA that meets modern requirements for clinical efficacy, safety, and cost-effectiveness.
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (9) , 6529
Open AccessExpert opinion on key aspects of managing education school for patients taking vitamin K antagonists
The leading problem in the use of vitamin K antagonist (VKA) therapy is the complexity and the need to maintain the international normalized ratio (INR) within therapeutic window of at least 60% of the treatment time. Obviously, the optimal solution to this problem in the context of modern technological capabilities is its self-monitoring by a patient and understanding the need to adjust the VKA (warfarin) dose to achieve the target INR values (independently or with the help of a physician’s consultation). Portable devices and a model of self-monitoring of anticoagulant therapy (coagulometers) has reduced the rates of thromboembolism, major bleeding, and all-cause mortality, and confirmed its high cost-effectiveness.An important aspect for successful INR self-monitoring is comprehensive patient education, implemented within the specialized schools. Such educational programs provide patients with the necessary knowledge about warfarin, the importance of regular INR monitoring, the aspects of self-monitoring, possible complications and actions in emergency situations. The combination of structured training and subsequent INR self-monitoring contributes to a significant increase in therapy adherence and improved clinical outcomes. The results of systematic reviews and randomized trials confirm that patient participation in educational programs reduces the risk of thromboembolic and hemorrhagic events and increases the overall effectiveness of treatment. The aim of the work was to formulate the key aspects of managing an education school for patients taking VKA.The combination of educational programs, active follow-up, coagulometers, and remote monitoring forms a holistic model for managing patients receiving VKA that meets modern requirements for clinical efficacy, safety, and cost-effectiveness.